Perella Weinberg Partners Capital Management LP Acquires 1,905 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Perella Weinberg Partners Capital Management LP grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 10.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 19,431 shares of the biopharmaceutical company’s stock after purchasing an additional 1,905 shares during the quarter. Perella Weinberg Partners Capital Management LP’s holdings in Bristol-Myers Squibb were worth $99,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $797,038,000. Oregon Public Employees Retirement Fund raised its holdings in shares of Bristol-Myers Squibb by 2,326.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 8,850,072 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd raised its holdings in shares of Bristol-Myers Squibb by 6,090.3% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock worth $214,700,000 after acquiring an additional 4,063,712 shares during the period. Prudential Financial Inc. raised its holdings in shares of Bristol-Myers Squibb by 90.9% during the fourth quarter. Prudential Financial Inc. now owns 4,967,474 shares of the biopharmaceutical company’s stock worth $257,891,000 after acquiring an additional 2,365,961 shares during the period. Finally, Ronna Sue Cohen raised its holdings in shares of Bristol-Myers Squibb by 4,702.2% during the first quarter. Ronna Sue Cohen now owns 1,518,227 shares of the biopharmaceutical company’s stock worth $1,518,000 after acquiring an additional 1,486,612 shares during the period. Institutional investors own 77.65% of the company’s stock.

In other news, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II acquired 5,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was purchased at an average cost of $47.29 per share, with a total value of $236,450.00. Following the transaction, the director now owns 27,000 shares in the company, valued at $1,276,830. The disclosure for this purchase can be found here. Company insiders own 0.12% of the company’s stock.

A number of brokerages recently commented on BMY. Goldman Sachs Group began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price objective on the stock. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective on the stock. in a report on Monday, May 20th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Tuesday, May 7th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Saturday, May 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Bristol-Myers Squibb in a research note on Friday, May 3rd. They issued an “overweight” rating and a $62.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $56.69.

Shares of BMY stock opened at $47.63 on Thursday. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69. The firm has a market capitalization of $76.67 billion, a price-to-earnings ratio of 11.97, a price-to-earnings-growth ratio of 2.19 and a beta of 0.74.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period in the previous year, the business earned $0.94 EPS. The company’s revenue was up 14.0% compared to the same quarter last year. Research analysts expect that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2019/06/13/perella-weinberg-partners-capital-management-lp-acquires-1905-shares-of-bristol-myers-squibb-co-nysebmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What Does Beta Mean In Stock Selection

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.